Revance price target lowered to $30 from $33 at Goldman Sachs

Goldman Sachs analyst Chris Shibutani lowered the firm’s price target on Revance to $30 from $33 but keeps a Buy rating on the shares. The company’s Q3 results represent a snapshot into a work-in-progress following the material shift in its commercialization strategy with Daxxify, the analyst tells investors in a research note. The therapeutic launch update is also unchanged and on track with PrevU in CD following its August approval, though the launch challenges amid negative sentiment remain considerable, the firm added.